CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $128.17M, lower than 95% of all stocks globally
- PositionGross margin is 87.2%, higher than 95% of its Medical Devices peers (median 61%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
128.17MUSDvs all stocks (USD)
Revenue (TTM)
59.07MUSDvs all stocks (USD)
Profit Margin
-89.14%vs Medical Devices peers
Beta
0.7680xvs all stocks
52-Week Change
-15.70%vs all stocks
Market Capitalization
128.17MUSDvs all stocks (USD)
Enterprise Value
116.32MUSDvs all stocks (USD)
Forward P/E
-2.55xvs Medical Devices peers
Price to Sales (TTM)
2.17xvs Medical Devices peers
Price to Book (MRQ)
4.39xvs Medical Devices peers
Enterprise to Revenue
1.97xvs Medical Devices peers
Enterprise to EBITDA
-2.36xvs Medical Devices peers
Gross Margin
87.22%vs Medical Devices peers
Profit Margin
-89.14%vs Medical Devices peers
Operating Margin
-82.34%vs Medical Devices peers
Return on Assets (TTM)
-27.25%vs Medical Devices peers
Return on Equity (TTM)
-106.96%vs Medical Devices peers
Revenue (TTM)
59.07MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.25USDUpdated Jul 9, 2026Quarterly Revenue Growth
19.60%vs Medical Devices peers
Gross Profit (TTM)
50.91MUSDvs all stocks (USD)
EBITDA (TTM)
-49.21MUSDvs all stocks (USD)
Net Income (TTM)
-52.66MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
19.61%vs Medical Devices peers
Operating Cash Flow (TTM)
-39.57MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-23.05MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 9, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
56.65MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
8.31MUSDFY2025 · Dec 31, 2025Gross Profit
48.34MUSDFY2025 · Dec 31, 2025Operating Income
-51.27MUSDvs all stocks (USD)
Pre-tax Income
-53.32MUSDFY2025 · Dec 31, 2025Income Tax Expense
-18.00KUSDFY2025 · Dec 31, 2025Net Income
-53.31MUSDFY2025 · Dec 31, 2025EBIT
-47.50MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-46.74MUSDFY2025 · Dec 31, 2025Research & Development
11.13MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
88.47MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
5.83MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.04USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.04USDFY2025 · Dec 31, 2025Basic Shares Outstanding
26.08MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
26.08MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-53.31MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-41.50MUSDFY2025 · Dec 31, 2025Free Cash Flow
-42.08MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
75.71MUSDFY2025 · Dec 31, 2025Interest Paid
5.04MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-53.31MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
756.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
11.05MUSDFY2025 · Dec 31, 2025Other Non-cash Items
241.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.40MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.25MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-98.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-580.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-580.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
8.97MUSDFY2025 · Dec 31, 2025Shares Outstanding
26.43MSharesUpdated Jul 9, 2026Float Shares
18.33MSharesUpdated Jul 9, 2026Shares Short
1.94MSharesUpdated Jul 9, 2026Short Ratio
5.23daysvs all stocks
Short % of Shares Outstanding
10.27%vs all stocks
% Held by Insiders
9.55%vs all stocks
% Held by Institutions
63.57%vs all stocks
Total Cash (MRQ)
72.30MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.73USDUpdated Jul 9, 2026Total Debt (MRQ)
59.40MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
2.04xvs Medical Devices peers
Current Ratio (MRQ)
10.20xvs Medical Devices peers
Book Value per Share (MRQ)
1.10USDUpdated Jul 9, 2026Total Assets
104.79MUSDvs all stocks (USD)
Total Current Assets
101.65MUSDFY2025 · Dec 31, 2025Total Liabilities
65.47MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.15MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
52.15MUSDFY2025 · Dec 31, 2025Total Current Liabilities
13.32MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
75.71MUSDFY2025 · Dec 31, 2025Accounts Receivable
10.66MUSDFY2025 · Dec 31, 2025Inventory
12.21MUSDFY2025 · Dec 31, 2025Accounts Payable
3.83MUSDFY2025 · Dec 31, 2025Short-term Debt
352.00KUSDFY2025 · Dec 31, 2025Long-term Debt
50.15MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
2.00MUSDFY2025 · Dec 31, 2025Common Stock (Book)
263.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-590.65MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
39.32MUSDvs all stocks (USD)
52-Week Low
4.37USDUpdated Jul 9, 202652-Week High
11.30USDUpdated Jul 9, 202652-Week Change
-15.70%vs all stocks
Beta
0.7680xvs all stocks
50-Day MA
6.52USDUpdated Jul 9, 2026200-Day MA
7.75USDUpdated Jul 9, 2026Avg 10-Day Volume
280.42KSharesUpdated Jul 9, 2026Avg 30-Day Volume
353.42KSharesUpdated Jul 9, 2026Diluted EPS (TTM)
-2.01USDUpdated Jul 9, 2026Other Income / Expense
3.77MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 87.2%, higher than 95% of its Medical Devices peers (median 61%)Significant
Gross margin: 0.87Industry median: 0.61Industry P95: 0.85Peers compared: 102
Operating margin is -82.3%, lower than 95% of its Medical Devices peers (median 8.1%)Significant
Operating margin: -0.82Industry median: 0.08Industry P5: -0.73Peers compared: 102
Return on equity is -107%, lower than 95% of its Medical Devices peers (median 3%)Significant
Return on equity: -1.07Industry median: 0.03Industry P5: -0.69Peers compared: 102
Debt-to-equity is 2.04×, higher than 95% of its Medical Devices peers (median 0.11×)Significant
Debt-to-equity: 2.04Industry median: 0.11Industry P95: 1.20Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.87Profit Margin: -0.89
Significant cash reserves alongside high leverageNotable
Cash (USD): 72,303,000Total Debt (USD): 59,395,000Debt-to-Equity: 2.04
Financial Health
Consistent revenue growth patternNotable
Growth Consistency Score: 0.51
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $128.17M, lower than 95% of all stocks globallySignificant
Market cap (USD): 128,168,609Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow
3Billion Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
PepGen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cellbion Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Curacle Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Scancell Holdings Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Futurechem Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nibec Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Polaryx Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Engene Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shenzhen Wongtee International Enterprise Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Blackbaud Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Anavex Life Sciences Corp.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated